Keywords: Repligen, RG2417, Bipolar depression, Ph IIb

Repligen plunges as bipolar drug flops in Ph IIb trial

Article | 08 March 2011

USA-based Repligen (Nasdaq: RGEN) saw its shares plummet 29.1% to $3.48 by mid-afternoon trading yesterday, after the company announced results of a ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Repligen

Go to company listing